Advanced search

Instruments

Name		Stock exchange	Average volume	Price	Type
HON HAI PRECISION INDUSTRY CO., LTD.	HNHP.F	OTC Markets +5 Other	47,116	11.01 USD	Stock
HON HAI PRECISION INDUSTRY CO., LTD.	HHP2	Deutsche Boerse AG	-	9.95 EUR
HON HAI PRECISION INDUSTRY CO., LTD.	HHPD	London S.E.	71,227	10.98 USD
HON HAI PRECISION INDUSTRY CO., LTD.	HHP2	Börse Stuttgart	-	9.9 EUR
HON HAI PRECISION INDUSTRY CO., LTD.	HHP2	BOERSE MUENCHEN	673	10.1 EUR
HON HAI PRECISION INDUSTRY CO., LTD.	HHP1	Berne S.E.	-	- CHF
HON HAI PRECISION INDUSTRY CO., LTD.	2317	Taiwan S.E. +1 Other	92,973,551	180.5 TWD	Stock
HON HAI PRECISION INDUSTRY CO., LTD.	HNHA.F	OTC Markets	-	3.256 USD
HAI LECK	BLH	Singapore S.E.	2,833	0.355 SGD	Stock
HAI-O ENTERPRISE	BESHOM	BURSA MALAYSIA	223,193	0.97 MYR	Stock
HAI PHAT INVESTMENT	HPX	Ho Chi Minh S.E.	6,548,927	7,200 VND	Stock
HAI PHONG ELECTRICAL MECHANICAL	DHP	HANOI S.E.	4,148	11,300 VND	Stock
LIM SEONG HAI CAPITAL	LSH	BURSA MALAYSIA	70,353	0.88 MYR	Stock
HUNG SHENG CONSTRUCTION LTD.	2534	Taiwan S.E.	2,888,938	25.8 TWD	Stock
WAN HAI LINES LTD.	2615	Taiwan S.E.	58,004,961	85.6 TWD	Stock
SHIN HAI GAS CORPORATION	9926	Taiwan S.E.	15,213	55.2 TWD	Stock

See all

News (115)

Xander International Corp. Announces Resignation of He,Bin-Hai as CFO and Changes in Financial Officer, Accounting Officer, Corporate Governance Officer	15/05	CI
Shanghai Hansoh Biomedical Technology Company Limited and Jiangsu Hansoh Pharmaceutical Group Company Limited Receives Clinical Trial Notice	10/11	CI
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of "HS-20105"	25/23/25	CI
Great Taipei Gas : To elect Directors and Independent Directors at 2022 Annual General Shareholders' Meeting.	23/22/23	PU
Advancetek : Announcement of the approval of release the Prohibition on Directors from Participation in Competitive Business at 2022 shareholders meeting	15/22/15	PU
Taiwan Steel Union : Announcement for the removal of the non-compete clause for directors	26/22/26	PU
Taiwan Steel Union : Important resolutions of the Company's 2022 regular shareholders meeting	26/22/26	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - JS103 INJECTION RECEIVED THE CLINICAL TRIAL APPROVAL	12/21/12	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - PD-1/TGF-BETA BIFUNCTIONAL FUSION PROTEIN JS201 INJECTION RECEIVED THE CLINICAL TRIAL APPROVAL	07/21/07	PU
Sheng Ye Capital : DISCLOSEABLE TRANSACTIONS - ENTRY OF THE THIRD SUPPLEMENTAL REFACTORING AGREEMENT (CUSTOMER HJ), THE SUPPLEMENTAL FACTORING AGREEMENTS AND THE FACTORING AGREEMENT (CUSTOMER SHKX)	30/21/30	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT / INSIDE INFORMATION - SHANGHAI JUNSHI BIOSCIENCES CO., LTD. 2021 FIRST QUARTERLY REPORT	29/21/29	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - XPO1 INHIBITOR JS110 RECEIVED THE CLINICAL TRIAL APPROVAL	26/21/26	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - TORIPALIMAB PLUS CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR ADVANCED OR METASTATIC ESOPHAGEAL CANCER REACHED PRIMARY ENDPOINTS IN A PHASE III CLINICAL STUDY	22/21/22	PU
China East Education : PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; RE-ELECTION OF RETIRING DIRECTORS; RE-APPOINTMENT OF AUDITORS; DECLARATION OF A FINAL DIVIDEND; A SPECIAL DIVIDEND OUT OF THE SHARE PREMIUM ACCOUNT; AND NOTICE OF ANNUAL GENERAL MEETING	22/21/22	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - APPROVAL GRANTED TO SUPPLEMENTAL NEW DRUG APPLICATION FOR TORIPALIMAB FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WHO FAILED PLATINUM-CONTAINING CHEMOTHERAPY	12/21/12	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - JS007 INJECTION RECEIVED THE ACCEPTANCE NOTICE FOR THE INVESTIGATIONAL NEW DRUG APPLICATION	07/21/07	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE CONVENING OF THE 2020 ANNUAL RESULTS BRIEFING	31/21/31	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON APPOINTMENT OF SECURITIES AFFAIRS REPRESENTATIVE	30/21/30	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON INVESTMENT IN ANWITA AND RELATED PARTY TRANSACTION	30/21/30	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON RE-ELECTION OF THE NEW SESSION OF THE BOARD OF SUPERVISORS	30/21/30	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON RE-ELECTION OF THE NEW SESSION OF THE BOARD OF DIRECTORS	30/21/30	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON ADDITION OF ESTIMATED EXTERNAL GUARANTEE QUOTA FOR 2021	30/21/30	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE TEMPORARY REPLENISHMENT OF LIQUIDITY BY USING PART OF THE IDLE PROCEEDS	30/21/30	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD. SPECIAL REPORT ON THE DEPOSIT AND ACTUAL USE OF PROCEEDS FOR THE YEAR OF 2020	30/21/30	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE RESOLUTIONS OF THE THIRTY-FOURTH MEETING OF THE SECOND SESSION OF THE BOARD OF DIRECTORS	30/21/30	PU
Shanghai Junshi Biosciences : CHANGE OF REGISTERED ADDRESS IN THE PRC AND OTHER PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION, THE RULES OF PROCEDURES OF THE GENERAL MEETINGS, THE BOARD OF DIRECTORS AND THE BOARD OF SUPERVISORS	30/21/30	PU
Shanghai Junshi Biosciences : NOTICE OF THE 2021 FIRST CLASS MEETING OF H SHAREHOLDERS	30/21/30	PU
Shanghai Junshi Biosciences : FORM OF PROXY FOR THE 2020 ANNUAL GENERAL MEETING TO BE HELD ON TUESDAY, 29 JUNE 2021	30/21/30	PU
Shanghai Junshi Biosciences : NOTICE OF THE 2020 ANNUAL GENERAL MEETING	30/21/30	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - TORIPALIMAB HAS BEEN INCLUDED IN DRUG LIST OF THE PROCEDURE FOR BREAKTHROUGH THERAPY DESIGNATION	24/21/24	PU
SITC International : ANNUAL REPORT 2020	22/21/22	PU
Shenzhen Expressway : Joint Announcement - Discloseable Transaction - Acquisition of Office Property	08/21/08	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - JS103 INJECTION RECEIVED THE ACCEPTANCE NOTICE FOR THE INVESTIGATIONAL NEW DRUG APPLICATION	05/21/05	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - INITIATING ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR TORIPALIMAB WITH FDA FOR THE TREATMENT OF NASOPHARYNGEAL CARCINOMA	03/21/03	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - ENTERING INTO AN EXCLUSIVE PROMOTION AGREEMENT WITH ASTRAZENECA PHARMACEUTICAL	01/21/01	PU
Shanghai Junshi Biosciences : INSIDE INFORMATION - 2020 PRELIMINARY RESULTS ANNOUNCEMENT	26/21/26	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - PD-1/TGF-BETA BIFUNCTIONAL FUSION PROTEIN JS201 INJECTION RECEIVED THE ACCEPTANCE NOTICE FOR THE INVESTIGATIONAL NEW DRUG APPLICATION	24/21/24	PU
Baker Hughes : Conflict Minerals Reporting Template (CMRT) 2019	18/20/18	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - TORIPALIMAB FOR TREATMENT OF SOFT TISSUE SARCOMA IS GRANTED THE ORPHAN-DRUG DESIGNATION BY THE FDA	17/20/17	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE TECHNOLOGY TRANSFER AND COOPERATION AGREEMENT WITH WIGEN BIOMEDICINE	16/20/16	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - UPDATE ON PROGRESS FOR TORIPALIMAB INJECTION	10/20/10	PU
Shanghai Junshi Biosciences : FORMATION OF A JV COMPANY TO JOINTLY DEVELOP CD39 DRUG	09/20/09	PU
Shanghai Junshi Biosciences : VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE LICENSE CONTRACT WITH LETO LABORATORIES	28/20/28	PU
Shanghai Junshi Biosciences : CHANGE IN USE OF PROCEEDS FROM THE GLOBAL OFFERING OF H SHARES AND SUPPLEMENTAL INFORMATION IN RELATION TO THE 2019 ANNUAL REPORT ON USE OF PROCEEDS	28/20/28	PU
Shanghai Junshi Biosciences : OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* ANNOUNCEMENT ON THE FULFILLMENT OF EXERCISE CONDITIONS FOR THE FIRST EXERCISE PERIOD UNDER THE 2018 SHARE OPTION INCENTIVE SCHEME	28/20/28	PU

123NextSee all

Companies (96)

ASAHI GROUP HOLDINGS, LTD. 18 309 M $

Asahi Group Holdings, Ltd. specializes in the production and marketing of beer and non alcoholic beverages. Net sales break down by family of products as follows: - alcoholic beverages (31%): beer, liqueurs, wine and whisky (brands Asahi Super Dry, Asahi ...

HON HAI PRECISION INDUSTRY CO., LTD. 77 251 M $

Hon Hai Precision Industry Co Ltd is a Taiwan-based company mainly engaged in the provision of various connectors, housings, radiators, assembled products and related products related to the information industry, communication industry, automation equipme ...

WUS PRINTED CIRCUIT (KUNSHAN) CO., LTD. 8 206 M $

WUS PRINTED CIRCUIT (KUNSHAN) CO., LTD. is a China-based company, principally engaged in the manufacture, distribution and after-sale services of printed circuit boards (PCBs). Its products include enterprise communication market boards, office and indust ...

CNH INDUSTRIAL N.V. 13 216 M $

CNH Industrial N.V. is an equipment and services company. The Company is engaged in the design, production, marketing, sale, and financing of agricultural and construction equipment. The Company operates through three segments: Agriculture, Construction a ...

SHENG SIONG GROUP LTD 1 669 M $

Sheng Siong Group Ltd. is an investment holding company that operates supermarket chain in Singapore. The Company operates approximately 68 outlets across Singapore. The outlets provide its customers with both wet and dry shopping options, including a wid ...

FREIGHT TECHNOLOGIES 17 M $

China Internet Nationwide Financial Services Inc is a holding company. The Company is engaged in the business of providing financial advisory services small-to-medium sized enterprises (SMEs). The Company, through its subsidiaries offers commercial paymen ...

HAI AN TRANSPORT AND STEVEDORING 175 M $

Hai An Transport and Stevedoring Joint Stock Company (HAIANTS) is a Vietnam-based firm, which has been involved in maneuvering the Hai An marine port in Hai Phong City. The Companyâs regular undertakings are container loading, freight transporting, ship ...

WINGARA AG LIMITED 1 M $

Wingara AG Limited is an Australia-based company. The Company is engaged in the sale of agricultural products to the domestic and international markets, particularly focusing on the export of hay products to Asia. The Company is an owner and operator of v ...

FORTUNE SUN (CHINA) HOLDINGS LIMITED 4 M $

Fortune Sun (China) Holdings Limited is a Hong Kong-based investment holding company principally engaged in property businesses. The main businesses of the Company include the provision of comprehensive property consultancy and sales agency services, as w ...

HENG SHENG HOLDING GROUP LIMITED 26 M $

Heng Sheng Holding Group Limited is a Hong Kong-based company primarily engaged in the manufacture and distribution of Toys. The Companyâs products include sewing toys and plastic toys under the brand names of JAZZIT and HENGSHENG. The Company distribut ...

1234Next

Insiders

Hai Sheng Wu

Hai Sheng Wu currently works at Zhuhai Livzon Diagnostics, Inc., as Member-Supervisory Board.

Hai Sheng Wu

Hai Sheng Wu founded 360 Finance, Inc. Currently, he is Chief Executive Officer & Director at this company. In his past career Mr. Wu held the position of Product Manager at Baidu, Inc. Mr. Wu received an undergraduate degree from Communication University of China and a graduate degree from Peking University.

Hai Sheng

Sheng Sheng Wu

Sheng Sheng Wu served as an Independent Director at Medigen Biotechnology Corp.
and Medigen Vaccine Biologics Corp.
from 2015 to 2018.
Wu holds an undergraduate degree from National Taiwan University and an MBA from National Sun Yat-Sen University.

Sheng Hai

Hai Wu

No results for this search